NASDAQ:VACC

Vaccitech (VACC) Stock Forecast, Price & News

$2.41

-0.02 (-0.82%)

(As of 06/2/2023 ET)

Compare

Today's Range: $2.31
▼
$2.47
50-Day Range: $2.19
▼
$2.51
52-Week Range: $2.02
▼
$7.45

Volume: 27,395 shs
Average Volume: 28,357 shs
Market Capitalization: $92.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.67

Vaccitech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 425.6% Upside
$12.67 Price Target
Short Interest: Healthy
0.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.00
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$36,575 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.39) to ($2.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

661st out of 983 stocks

Pharmaceutical Preparations Industry

330th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Vaccitech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.67, Vaccitech has a forecasted upside of 425.6% from its current price of $2.41.
Amount of Analyst Coverage
Vaccitech has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.06% of the float of Vaccitech has been sold short.
Short Interest Ratio / Days to Cover
Vaccitech has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vaccitech has recently increased by 43.66%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Vaccitech does not currently pay a dividend.
Dividend Growth
Vaccitech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VACC.

2.2

News and Social Media Coverage

News Sentiment
Vaccitech has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Vaccitech this week, compared to 2 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaccitech insiders have bought 0.76% more of their company's stock than they have sold. Specifically, they have bought $36,575.00 in company stock and sold $36,300.00 in company stock.
Percentage Held by Insiders
Only 6.00% of the stock of Vaccitech is held by insiders.
Percentage Held by Institutions
Only 27.07% of the stock of Vaccitech is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Vaccitech are expected to decrease in the coming year, from ($2.39) to ($2.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vaccitech is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaccitech is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaccitech has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vaccitech (NASDAQ:VACC) Stock

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Receive VACC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

VACC Stock News Headlines

June 3, 2023 | americanbankingnews.com

Robin Wright Buys 13,750 Shares of Vaccitech plc (NASDAQ:VACC) Stock

May 19, 2023 | finance.yahoo.com

Newsflash: Vaccitech plc (NASDAQ:VACC) Analysts Have Been Trimming Their Revenue Forecasts

June 3, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 17, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Arcus Biosciences (RCUS), Vaccitech Plc (VACC)

May 16, 2023 | msn.com

Morgan Stanley Maintains Vaccitech plc - ADR (VACC) Overweight Recommendation

May 12, 2023 | msn.com

Vaccitech: Q1 Earnings Insights

May 12, 2023 | finance.yahoo.com

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 5, 2023 | finance.yahoo.com

Revenues Working Against Vaccitech plc's (NASDAQ:VACC) Share Price

June 3, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

April 17, 2023 | finance.yahoo.com

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

March 31, 2023 | americanbankingnews.com

Insider Selling: Vaccitech plc (NASDAQ:VACC) CEO Sells 15,000 Shares of Stock

March 31, 2023 | americanbankingnews.com

HC Wainwright Equities Analysts Reduce Earnings Estimates for Vaccitech plc (NASDAQ:VACC)

March 30, 2023 | marketwatch.com

Global Influenza Vaccines Market Size 2023 to 2026 Size and Share Survey Report

March 30, 2023 | americanbankingnews.com

Short Interest in Vaccitech plc (NASDAQ:VACC) Declines By 16.6%

March 29, 2023 | markets.businessinsider.com

Vaccitech Plc (VACC) Gets a Buy from Morgan Stanley

March 29, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kodiak Sciences (KOD) and Vaccitech Plc (VACC)

March 29, 2023 | americanbankingnews.com

Vaccitech (NASDAQ:VACC) PT Lowered to $15.00

March 28, 2023 | finanznachrichten.de

Vaccitech plc: Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

March 28, 2023 | finance.yahoo.com

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

March 28, 2023 | americanbankingnews.com

Barclays Trims Vaccitech (NASDAQ:VACC) Target Price to $7.00

March 27, 2023 | msn.com

Vaccitech Earnings Perspective: Return On Capital Employed

March 27, 2023 | benzinga.com

UK leadership in health, food and sustainability prompts Milltrust to launch follow-on university venture fund.

March 27, 2023 | msn.com

New $150m fund set to invest in ‘high-impact’ firms across food and healthcare

March 25, 2023 | americanbankingnews.com

Vaccitech plc (NASDAQ:VACC) to Post FY2022 Earnings of $0.26 Per Share, HC Wainwright Forecasts

March 24, 2023 | finanznachrichten.de

Vaccitech plc: Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

March 24, 2023 | msn.com

Banking Sector Worries Weigh on American Depositary Receipts of European Equities

March 24, 2023 | benzinga.com

Vaccitech shares are trading higher after the company reported better-than-expected FY22 sales results.

See More Headlines

VACC Price History

30 days | 90 days | 365 days | Advanced Chart

VACC Company Calendar

Last Earnings: 3/24/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VACC
CUSIP: N/A
CIK: 1828185
Web: www.vaccitech.co.uk
Phone: 44-18-6581-8808
Fax: N/A
Employees: 72
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.67
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +425.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $5.34 million
Net Margins: -51.19%
Pretax Margin: -65.00%
Return on Equity: -6.33%
Return on Assets: -5.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.74
Quick Ratio: 16.74

Sales & Book Value

Annual Sales: $44.70 million
Price / Sales: 2.07
Cash Flow: $0.25 per share
Price / Cash Flow: 9.47
Book Value: $6.09 per share
Price / Book: 0.40

Miscellaneous

Outstanding Shares: 38,350,000
Free Float: 36,048,000
Market Cap: $92.42 million
Optionable: Not Optionable
Beta: 0.16

Key Executives

Mr. William J. Enright MBA (Age 59)
CEO & Director
Comp: $754.28k

Dr. Margaret Marshall M.D. (Age 65)
Chief Medical Officer
Comp: $547.97k

Ms. Sarah Gilbert
Co-Founder

Mr. Adrian Hill Ph.D.
Co-Founder & Scientific Advisor

Ms. Gemma Brown
Chief Financial Officer

Mr. Chris Ellis (Age 62)
Chief Operating Officer

Dr. Thomas George Evans M.D. (Age 67)
Chief Scientific Officer

Mr. Graham Griffiths (Age 43)
Chief Bus. Officer

Ms. Elizabeth Eagling-Vose M.B.A.
Head of Clinical Operations

Bernie McDonald
Head of IP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VACC Stock - Frequently Asked Questions

Should I buy or sell Vaccitech stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VACC shares.
View VACC analyst ratings or view top-rated stocks.
What is Vaccitech's stock price forecast for 2023?: 2 Wall Street research analysts have issued 12-month target prices for Vaccitech's shares. Their VACC share price forecasts range from $7.00 to $16.00. On average, they predict the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 425.6% from the stock's current price.
View analysts price targets for VACC or view top-rated stocks among Wall Street analysts.
How have VACC shares performed in 2023?: Vaccitech's stock was trading at $2.35 on January 1st, 2023. Since then, VACC stock has increased by 2.6% and is now trading at $2.41.
View the best growth stocks for 2023 here.
Are investors shorting Vaccitech?: Vaccitech saw a increase in short interest in May. As of May 15th, there was short interest totaling 20,400 shares, an increase of 43.7% from the April 30th total of 14,200 shares. Based on an average daily volume of 52,800 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the company's stock are short sold.
View Vaccitech's Short Interest.
When is Vaccitech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VACC earnings forecast.
How were Vaccitech's earnings last quarter?: Vaccitech plc (NASDAQ:VACC) posted its quarterly earnings results on Friday, March, 24th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.12. The company had revenue of $6.46 million for the quarter, compared to analysts' expectations of $3.07 million. Vaccitech had a negative net margin of 51.19% and a negative trailing twelve-month return on equity of 6.33%.

When did Vaccitech IPO?: (VACC) raised $110 million in an initial public offering on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.
What is Vaccitech's stock symbol?: Vaccitech trades on the NASDAQ under the ticker symbol "VACC."
Who are Vaccitech's major shareholders?: Vaccitech's stock is owned by a number of retail and institutional investors. Top institutional investors include Liontrust Investment Partners LLP (1.19%), Ipswich Investment Management Co. Inc. (0.07%) and Renaissance Technologies LLC (0.03%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Karen A Dawes, M&G Investment Management Ltd, Robin Wright, Sciences Innovation Plc Oxford and William Enright.
View institutional ownership trends.
How do I buy shares of Vaccitech?: Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vaccitech's stock price today?: One share of VACC stock can currently be purchased for approximately $2.41.
How much money does Vaccitech make?: Vaccitech (NASDAQ:VACC) has a market capitalization of $92.42 million and generates $44.70 million in revenue each year. The company earns $5.34 million in net income (profit) each year or ($0.40) on an earnings per share basis.
How can I contact Vaccitech?: Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The official website for the company is www.vaccitech.co.uk. The company can be reached via phone at 44-18-6581-8808 or via email at ir@vaccitech.co.uk..

This page (NASDAQ:VACC) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial